Navigation Links
ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
Date:9/21/2010

MOUNTAIN VIEW, Calif., Sept. 21 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it reported positive preclinical and Phase I study results at the European Association for the Study of Diabetes (EASD).  CCX140, a novel, orally bioavailable small molecule antagonist of the chemokine receptor CCR2, improved metabolic function while significantly reducing inflammatory macrophages found in adipose tissue in an animal model, and was well tolerated in Phase I clinical trials.  These data were presented today in a poster presentation entitled "CCR2 Antagonist CCX140-B in Phase 2 for Diabetes" in Stockholm, Sweden.  Data from an ongoing Phase II clinical trial in patients with type 2 diabetes mellitus is expected by the end of 2010 or early 2011.  

Results showed that daily treatment with CCX140 significantly improved fasting glucose and ameliorated insulin resistance (HOMA-IR) in obese, diabetic mice over a 28 day treatment period without a corresponding increase in MCP-1 (also called chemokine ligand 2 (CCL2)), the main ligand for CCR2.  Circulating adiponectin levels were significantly reduced in obese, diabetic mice and this was reversed when treated with CCX140.  The metabolic improvements also correlated with a significant reduction in adipose tissue inflammatory macrophage numbers. The preclinical studies were followed by Phase I clinical trials in 88 healthy human subjects.  These Phase I studies comprised single and multiple ascending dose placebo-controlled administration of CCX140 at doses ranging from 0.05 mg to 10 mg per day.  CCX140 was well tolerated in the Phase I trials with a favorable pharmacokinetic profile suitable for 5 to 10 mg once-daily oral treatment.  A Phase II clinical trial in 140 subjects with type 2 diabetes mellitus on stable doses of metformin was initiated earlier this year based on these encouraging preclinical and Phase I clinical results. The Phase II clinical trial is ongoi
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. Spherix Reports Second Quarter Earnings
11. Tapestry Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces that a ... catalogue: North America Laparoscopes Market Outlook ... North America Laparoscopes Market Outlook to ... America Laparoscopes Market Outlook to 2020", provides key ... The report provides value, in millions of US ...
(Date:8/28/2014)... 2014 /PRNewswire-iReach/ -- CountryFocus: Healthcare, Regulatory and Reimbursement ... (Photo - http://photos.prnewswire.com/prnh/20140828/140879 ) ... Reimbursement Landscape Poland " an essential source of ... healthcare market and provides insights into the demographic, ... the report provides valuable insights into the trends ...
(Date:8/28/2014)... China , Aug. 28, 2014 ... TPI ), a pharmaceutical company that specializes in ... generics and active pharmaceutical ingredients (API) today updates ... Company,s Qionglai Facility (QLF). The ... Practice (GMP) dataset for China Food & Drug ...
Breaking Medicine Technology:North America Laparoscopes Market Outlook to 2020 2North America Laparoscopes Market Outlook to 2020 3North America Laparoscopes Market Outlook to 2020 4North America Laparoscopes Market Outlook to 2020 5North America Laparoscopes Market Outlook to 2020 6North America Laparoscopes Market Outlook to 2020 7North America Laparoscopes Market Outlook to 2020 8North America Laparoscopes Market Outlook to 2020 9North America Laparoscopes Market Outlook to 2020 10North America Laparoscopes Market Outlook to 2020 11Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2
... Reportlinker.com announces that a new market research ... Patient Self-Monitoring: Devices, Markets, Players ... http://www.reportlinker.com/p0581171/Patient-Self-Monitoring-Devices-Markets-Players-and-Prospects .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic The ... serum levels is deemed to be a ...
... A new patent covering tumor suppression technologies, including the ... awarded to The University of Texas System ... to the discovery that chromosome 3p21.3 genes act as ... also known as FUS1, the anti-cancer agent in ...
Cached Medicine Technology:Patient Self-Monitoring: Devices, Markets, Players and Prospects 2Patient Self-Monitoring: Devices, Markets, Players and Prospects 3Genprex Announces New Patent Issuance in Japan 2
(Date:8/28/2014)... Amy Norton HealthDay Reporter ... have found that sending electrical currents through the scalp to ... for up to a day. In a small study ... to fire up certain networks involved in memory. That, in ... apparent 24 hours after the brain stimulation. During TMS, ...
(Date:8/28/2014)... "stuck fermentation," when yeast that should be busily converting ... down, leaving the remaining sugar to instead be consumed ... team of researchers including UC Davis yeast geneticist Linda ... problem. Working through a prion -- an abnormally ... enables bacteria in fermenting wine to switch yeast from ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Data from ... shows that while most hospitals utilize a basic electronic ... care information technology is still a challenge. , ... August issue of Health Affairs , and is ... Health Care Data Center, as well as Chantal Worzala, ...
(Date:8/28/2014)... New England Journal of Medicine published research results ... drug shown to safely reduce the viral load and ... respiratory syncytial virus (RSV). , Le Bonheur ... Center researcher Infectious Disease Specialist John DeVincenzo, MD, is ... is the most common cause of lower respiratory tract ...
(Date:8/28/2014)... the endangered Devils Hole pupfish, threatening the survival of this ... new research by the University of Nevada, Reno and Desert ... a small shelf near the surface of an isolated cavern ... up as a result of climate change and is likely ... water, which now reaches more than 93 degrees, has shortened ...
Breaking Medicine News(10 mins):Health News:Electrical Pulses to Scalp May Boost Memory: Study 2Health News:Electrical Pulses to Scalp May Boost Memory: Study 3Health News:Prions can trigger 'stuck' wine fermentations, researchers find 2Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 2Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 3Health News:DeVincenzo study breakthrough in RSV research 2Health News:Climate change puts endangered Devils Hole pupfish at risk of extinction 2Health News:Climate change puts endangered Devils Hole pupfish at risk of extinction 3
... (HealthDay News) -- Use of electronic medical records has had ... U.S. hospitals, suggests a new study. But the problem may ... assess its effectiveness. Researchers at the nonprofit RAND Corp. ... heart failure, heart attack and pneumonia -- at 2,021 hospitals ...
... Thompson HealthDay Reporter , THURSDAY, Dec. 23 (HealthDay ... of old age, with people,s joints growing creaky and painful ... thousands of kids in the United States. Children and teens ... impaired mobility if the disease isn,t caught in time. ...
... fried fish, could be one reason people in Alabama and ... Americans to die of a stroke, according to a study ... the medical journal of the American Academy of Neurology (AAN). ... Georgia, Louisiana, Mississippi, North Carolina, South Carolina and Tennessee ...
... By Serena Gordon HealthDay Reporter , WEDNESDAY, Dec. ... to have seizures into adolescence and beyond face a significantly ... new research suggests. In a study that followed ... found that 24 percent died during that time period. That,s ...
... corticosteroids act to increase production of red blood ... class of drugs that may be beneficial in ... Diamond-Blackfan anemia (DBA), which is frequently treated with ... of drugs may be able to treat other ...
... , WEDNESDAY, Dec. 22 (HealthDay News) -- New research suggests ... pill: a protein on their surfaces that gives them the ability ... challenge now, the researchers say, is to figure out how to ... "don,t eat me" signal. A study published online Dec. ...
Cached Medicine News:Health News:Electronic Health Records May Not Always Improve Care 2Health News:Doctor Shortage Adds to Pain of Juvenile Arthritis 2Health News:Doctor Shortage Adds to Pain of Juvenile Arthritis 3Health News:Doctor Shortage Adds to Pain of Juvenile Arthritis 4Health News:America's stroke belt partially fueled by fried fish 2Health News:Death Rates Higher for Those With Lasting Epilepsy: Study 2Health News:Death Rates Higher for Those With Lasting Epilepsy: Study 3Health News:Emerging drug class may enhance red blood cell production in anemic patients 2Health News:Emerging drug class may enhance red blood cell production in anemic patients 3Health News:Cancer Cells May Be Able to Urge Their Own Death 2